“Thank you for your interest in the company. We are a global advisory firm specializing in cross-border deal flow focused in China’s healthcare industry. The firm is the leading platform to facilitate partnerships to fuse Chinese capital, its large and fast-growing market with US/EU healthcare innovation.
With an experienced team of well-connected industry veterans from all over the world and the largest network in China’s healthcare industry, TPP has become the market expert with the top-notch network to execute and support cross-border transactions involving pharmaceuticals, medical devices and diagnostics.”
Tony Chu, Co-Founder, Partner
TPP Management
Tony Chu
Co-Founder / Managing Partner
With over 20 years of cross-border transaction experience in US/EU and Chinese chemical and pharmaceutical industries, Chu is the Founder and Managing Partner of TPP. He also sits as a Board Member for several companies including Eastar Chemical Corp, Pharma Partners Snd Bhd (Malaysia) and PT Inodia (Indonesia).
Asa Cox
Co-Founder / Partner
Cox is a Founding Partner of TPP. With over 20 years of healthcare licensing and business development experience, he has been globally connected since 1997 with a network of over 20,000 companies. Cox also serves as the Founder & CEO of Generic Pharma 2.0 and Chairman of GenericLicensing.com.
Mohd Zul Efendi
Partner for Malaysia
Efendi is a Partner at TPP, based in Malaysia. There he boosts 15 years of experience in the ASEAN healthcare industry and recently sat as Senior Manager and Head of Business Development at Pharmaniaga Berhad and BD Director at Biosis Group Berhad.
Ramlan Ibrahim
Partner for Malaysia
Ibrahim is a Partner at TPP, based in Malaysia. With 20 years of experience in pharmaceutical and healthcare in the ASEAN market, he was recently Senior General Manager of Global Sales & Marketing at Pharmaniaga.
Amiram Katzman
Partner
Katzman is a Partner of TPP. With 10+ years of experience in business development, he successfully connects clients with foreign markets and helps leverage their access to quality M&A and investment prospects. He currently serves Prodan Networks as CEO of the company.
Ivan Lo
Partner
With over 20 years senior executive experience in transnational pharmaceutical companies covering government affairs, finance, product registration and sales, etc. Ivan’s previous roles include Finance Director of Novartis China; Director of Operations at Wyeth China; and Finance Director of Nutricia in charge of operations and its pediatric nutrition department.
Nathan Tirtana
Partner
Mr. Tirtano is a partner at TPP South East Asia. He is the founder and major shareholder of a number life science companies in Indonesia and SE Asia, including the largest biosimilar and medical device diagnostics companies in Indonesia. Educated in Australia with decades of experience in SE Asia, he has a wide network and successful track record in the region’s life science sector.
Guang Yu
Partner
With over 15 years of business development experience, Guang possesses strong knowledge in government regulation and reimbursement. Previously, he is former Executive Director of several large Chinese pharma companies specializing in building relationships with government regulatory authorities and insurance reimbursement.
Directors
Angela Byrne
Director of Corporate Communications
With nearly a decade of Corporate Communications experience, through the Financial Services and Healthcare sectors, Byrne serves TPP as Head of Communications, both internally and externally. Previously, she held a managerial role at an international communications agency and currently sits on the Board for the American Cancer Society’s Distinguished Events Committee. Byrne holds a Masters of Corporate Communications, with a focus in Public Relations.
Jackie Cha
Director of Research
Cha serves TPP as Director of Research, with a focus on China healthcare market intelligence. With over 12 years of healthcare consulting experience, she has deep expertise in supporting transactions of sorts in healthcare space. Previously, Cha held a senior executive role at a China-based healthcare consulting practice.
Trisha Salerno
Director of Events
Salerno serves TPP as Director of Events, bringing more than a decade of experience conceptualizing, planning, promoting, managing and executing high profile, large scale events – ranging in format and geographical locations, with the goal of heightening participant satisfaction and elevating brand awareness. Prior to joining the TPP team, Salerno served as Senior Manager of Distinguished Events for the American Cancer Society and spent six years working for the Breast Cancer Research Foundation (BCRF) as the Associate Director of Development and Events.
Venture Partners
James Bruno
Venture Partner
Bruno is a Partner at TPP with 40+ years of Senior Executive experience, most notably with Honewell, Viachem, Aeroject and Sipsy. Previously, he was the Former President of the Drug, Chemical & Allied Technologies Association (DCAT) – the largest and oldest pharmaceutical association in the world.
José Luís Fábregas
Venture Partner
Dr. Fabregas is a venture partner at TPP. With decades of pharmaceutical development and licensing in/out experience, he is focused in advisory and consulting projects involving CMC, Pharma and Biotech. Prior to this, Dr. Fabregas was Senior Scientific Director of Pharmaceutical Development at Almirall, S.A.
Amiram Katzman
Venture Partner
Katzman is a Venture Partner of TPP. With 10+ years of experience in business development, he successfully connects clients with foreign markets and helps leverage their access to quality M&A and investment prospects. He currently serves Prodan Networks as CEO of the company.
Jeremy Kelly
Venture Partner
Jeremy is a venture partner at TPP. In addition, he is the founder and Director of Evidence Based Marketing and Deal Flow Ltd. Jeremy has over 3 decades of experience focusing on OTC with prior executive management in a number of MNCs, including Warner Wellcome, Reckitt Benckiser, and L’Oreal.
Shizhong Luo
Venture Partner
Mr. Luo has 20 years of experience managing cross border project, licensing and manufacturing between multnational national companies and Chinese enterprises. He held head of BD Positions at Yabao Pharmaceuticals, Xinhua Pharmceuticals and Board Secretary of JV between Xinhua and Perrigo. He is graduate of Peking University (Master of International Pharmceutical Engineer Management).
Xiao Shu, PhD
Venture Partner
Shu is a Venture Partner for TPP. Currently, Shu sits as the Managing Partner at Guijing Capital and owns 12 years of healthcare investment experience. Previously, he was the Former Portfolio Manager at Kangjing Capital, a healthcare Venture Capital. He graduated from University of California, Berkeley with a PhD degree in Metabolic Biology.
Johnson Zhong
Venture Partner
Johnson is a venture partner at TPP. Educated as a pharmacist, Johnson has extensive experience and track record with the Chinese regulatory agencies. He is previous experience are focused in executing regulatory approvals in China, market research and development and project management. He was previously head of drug regulatory affairs at Sandoz China.
Advisors
Harvey Fine
Advisor
Fine is an Advisor to the cross-border and emerging market private equity group at TPP. His expertise spans strategic partnerships/business development and M&A transactions with emphasis on China and India cross-border deals with the US and Europe. He also serves Fosun Group as the Managing Director in US-Global Investments & Strategies.
Frank Hong
Advisor
In addition to TPP, Mr. Hong is a Managing Director at Legend Capital, focusing on investments in Healthcare. Mr. Hong has rich experience in the pharmaceutical industry and investment in Healthcare. The investment portfolios he has led include: Kawin Technology, Innovent Biologics, PegBio , Baheal Pharmaceutical, Phiskin, Sciwin Biologics, Sinopharm Rfl etc. Prior to Legend Capital, Mr. Hong worked at ShiYu Capital, Nanjing University of Traditional Chinese Medicine, Bayer Healthcare. Mr. Hong holds a Bachelor’s degree from China Pharmaceutical University and a MBA from TongJi University.
Xielong Luo
Advisor
With over 30 years of experience in the Chinese healthcare industry, Mr Luo also currently holds these position: Vice Chairman of CPEA and head of its international steering committee; Vice Chair of China OTC Association; Director of Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province. His previous roles include: Director of the Medical Administration on Department of Hangzhou Board of Health, Chairman of National Medicine Research and Development Center; President of Chinese Academy of Sciences of Beijing General Pharmaceutical Corporation; VP of Beijing General Pharmaceutical Corporation, GM of Hangzhou Biological Medicine Industry investment Corporation. His advisory roles include China Medical Representative Office of the United Nations Industrial Development Organization (UNIDO), China’s “11th five-year plan” and “12th five-year plan” of Chinese Biological Medicine.
Lefei Sun
Advisor
Lefei currently serves as Founding Partner of HuaTai Healthcare Investment Fund. With more than 10 years of experience in healthcare analysis and M&A, he possesses strong knowledge in healthcare PE/VC investments in Greater China regions and cross-border deals, and supports global SME healthcare company in China market development.
Alex Xu
Advisor
Alex has over 20 years experience in China as Surgeon and executive management positions including Country Manager of CR Bard. Alex currently is Managing Partner of China Medtech Commercialization Fund 1 (CMC1). Chairman/CEO of Beijing GMT, an oncology focused diagnostic and device company in China.
Pei Zhou
Advisor
Pei is currently Partner of China Medtech Commercialization Fund 1 (CMC 1); Co-head of Pagoda Capital Healthcare. With more than 15 years of research and investment experience in the healthcare industry. Previously, Dr. Zhou served as a Senior Associate of China Everbright Limited Healthcare Investment Fund and has a vast reputation for sourcing, evaluating and the execution of equity investments in Pharmaceutical, medtech and healthcare services sub-sectors.
Strategic Alliances
Note: Partial List